These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8793891)

  • 1. Function of the GH/IGF-1 axis in healthy middle-aged male runners.
    Ambrosio MR; Valentini A; Trasforini G; Minuto F; Ghigo E; Cella S; Margutti A; Pansini R; degli Uberti EC
    Neuroendocrinology; 1996 Jun; 63(6):498-503. PubMed ID: 8793891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M; Bossoni S; Alí A; Doga M; Reimondo G; Milani G; Peretti P; Manelli F; Angeli A; Giustina A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine.
    Broglio F; Benso A; Gottero C; Vito LD; Aimaretti G; Fubini A; Arvat E; Bobbio M; Ghigo E
    Eur J Endocrinol; 2000 Feb; 142(2):157-63. PubMed ID: 10664524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated escape from GH autonegative feedback in midpuberty in males: evidence for time-delimited GH-induced somatostatinergic outflow in adolescent boys.
    Richmond E; Rogol AD; Basdemir D; Veldhuis OL; Clarke W; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3837-44. PubMed ID: 12161519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.
    Ghigo E; Goffi S; Arvat E; Imperiale E; Boffano GM; Valetto MR; Mazza E; Santi I; Magliona A; Boghen MF
    J Endocrinol Invest; 1992 Oct; 15(9):665-70. PubMed ID: 1479149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy.
    Broglio F; Fubini A; Morello M; Arvat E; Aimaretti G; Gianotti L; Boghen MF; Deghenghi R; Mangiardi L; Ghigo E
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):417-30. PubMed ID: 10468900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone.
    Bondanelli M; Ambrosio MR; Margutti A; Franceschetti P; Zatelli MC; degli Uberti EC
    Neuroendocrinology; 2003 Jun; 77(6):380-7. PubMed ID: 12845224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E; Ceda GP; Valcavi R; Goffi S; Zini M; Mucci M; Valenti G; Cocchi D; Müller EE; Camanni F
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
    Bellantoni MF; Harman SM; Cho DE; Blackman MR
    J Clin Endocrinol Metab; 1991 Jan; 72(1):172-8. PubMed ID: 1824707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
    Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
    J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.